Sanofi and Drugs for Neglected Diseases initiative (DNDi) announced today a three-year research collaboration agreement for the research of new treatments for nine neglected tropical diseases (NTDs), listed by the World Health Organization (WHO) for which new, adapted, and efficient tools are urgently needed to treat patients in endemic countries.
Sanofi today announced that data from eight compounds in the company’s robust oncology portfolio will be showcased in more than 100 abstracts at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 3-7, 2011.
Lauren Dousset är nu landschef på sanofi-aventis i Sverige och efterträder därmed Margarita Lopez Acosta. Sanofi-aventis är ett av världens största forskande läkemedelsföretag och fokuserar bland annat på onkologi, diabetes och hjärt-kärlsjukdomar.
Den 1 maj 2011 sänker vi kraftigt priset på Insuman Basal SoloSTAR vilket innebär att Insuman Basal SoloSTAR blir 20% billigare än Insulatard FlexPen. Därmed blir Insuman Basal SoloSTAR blir det billigaste NPH-insulinet i förfylld penna på den svenska marknaden.
Data som presenterades visar också att 70 procent av patienterna fick en förbättrad eller stabiliserad kognition efter behandling med Copaxone®. Data presenterade vid det 63:e årsmötet för American Academy of Neurology (AAN) i Honolulu på Hawaii.
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) presenterade under AAN preliminära data från två studier, Coptimize och QualiCop.
Den globala C
Ett helt nytt koncept håller på att växa fram på KS sjukhusområde . Höga förväntningar omger det redan "mytomspunna" Nya Karolinska Solna, NKS. Läs vårt senaste nummer av Santé med tema Nya Karolinska Solna.
Sanofi-aventis announced today that lixisenatide, a once-daily GLP-1 receptor agonist under development for people with Type 2 diabetes, achieved its primary efficacy objective of significant HbA1c reduction and improved glycemic control from baseline versus placebo. The top-line results also showed that people treated with lixisenatide had a significant decrease in body weight.
EU-kommissionen har nu godkänt Jevtana (cabazitaxel), i kombination med prednison eller prednisolon, för behandling av patienter med metastatisk hormonrefraktär prostatacancer (mHRPC) som tidigare fått docetaxel-baserad behandling. Resultat från TROPIC-studien visade att Jevtana ger mer än hälften av patienterna åtminstone ett år till att leva.
Sanofi-aventis will donate 1 million Euros to support the aid relief efforts of the Japan Red Cross through the Sanofi Espoir Foundation for the Tohoku Pacific Earthquake and Tsunami that struck the area on March 11, 2011. Additionally, an appeal for generosity has been launched across all countries and affiliates worldwide, inviting employees who wish to join in this solidarity effort.
Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today it had signed a new agreement to donate $25 million, extending its decade-long partnership with the World Health Organization (WHO) for another five years to control neglected tropical diseases, including the potentially fatal Human African Trypanosomiasis, also known as sleeping sickness.
CHMP inom EMA har gett ett positivt utlåtande (”positive opinion”) där de rekommenderar att JEVTANA® (cabazitaxel) ska godkännas för försäljning inom EU. Rekommendationen gäller JEVTANA® i kombination med prednison eller prednisolon, och avser behandling av patienter med metastatisk hormonrefraktär prostatacancer (mHRPC) som tidigare fått docetaxel-baserad behandling.
Sanofi-aventis and Ascendis Pharma announced today a global licensing and patent transfer agreement on Ascendis’ proprietary TransCon Linker and Hydrogel carrier technology, which allows for a drug compound to be released in the body in a precise, time-controlled fashion, creating a long-acting effect.
Stora regionala skillnader, brist på urologer och kunskapsluckor skapar en orättvis cancervård i Sverige. Det slog en enig debatt fast vid ett kvällsseminarium i Stockholm. Samtidigt visade panelen att det finns en stark vilja att förändra vården och skapa bättre förutsättningar för alla att få tillgång till god och kvalitativ vård.
Sanofi-aventis is pleased to announce the appointment of Dr. Elias Zerhouni as President, Global Research & Development, covering Medicines and Vaccines, effective January 1, 2011. Dr. Zerhouni will report directly to Christopher A. Viehbacher, Chief Executive Officer of sanofi-aventis, and join the Executive Committee and the Management Committee.
Commenting on the Group’s performance in Q3 2010, sanofi-aventis Chief Executive Officer, Christopher A. Viehbacher said, “This third quarter was marked by the success of the Jevtana® launch in the U.S., by positive Phase III data for lixisenatide and teriflunomide but also by the entry of a generic of Lovenox® in the U.S. Our Q3 results were also enhanced by favourable currency tailwind. Tight co
Sanofi-aventis announced today a research collaboration with Harvard University. The goal of the collaboration is to advance knowledge in the area of human health through basic and applied research and to promote scientific exchange between Harvard University and sanofi-aventis. The focus is translational biomedical research in multiple therapeutic areas such as cancer, diabetes and inflammation.
Sanofi-aventis announced today the results from the two year phase III TEMSO study of teriflunomide, a novel oral disease modifier investigated for the treatment of relapsing multiple sclerosis (RMS). In this study, both doses of teriflunomide (7 and 14mg) significantly reduced annualized relapse rate (primary study endpoint) by 31% vs. placebo (p≤0.0005).
Sanofi-aventis announced today that data from the Phase III TROPIC study, which was the basis for the June 2010 U.S. Food and Drug Administration (FDA) approval of Jevtana® (cabazitaxel) Injection, was published in the October 2 issue of The Lancet.
Sanofi-aventis announced today the top-line results of the GETGOAL-L-ASIA study assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, in combination with basal insulin.
I juli var många samlade till årets Almedalsvecka. Sanofi-aventis arrangerade fyra seminarier om aktuella frågor i hälsa och samhälle. I vår webb-tv har Du möjlighet att i korta tv-reportage få en sammanfattning av seminarierna.